Tysabri Analysis Finds No New Safety Concerns In Crohn's, RA Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan say the safety evaluation to return the multiple sclerosis therapy Tysabri to market is complete.